Zoetis Inc. $ZTS Shares Sold by Jag Capital Management LLC

Jag Capital Management LLC cut its stake in shares of Zoetis Inc. (NYSE:ZTS) by 2.0% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 13,007 shares of the company’s stock after selling 267 shares during the period. Jag Capital Management LLC’s holdings in Zoetis were worth $2,028,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ZTS. Nuveen LLC purchased a new position in shares of Zoetis in the first quarter valued at $616,375,000. Mackenzie Financial Corp lifted its holdings in Zoetis by 4,158.3% in the 1st quarter. Mackenzie Financial Corp now owns 1,824,967 shares of the company’s stock worth $300,481,000 after buying an additional 1,782,110 shares in the last quarter. Polen Capital Management LLC lifted its holdings in Zoetis by 17.6% in the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock worth $1,448,401,000 after buying an additional 1,313,653 shares in the last quarter. Amundi lifted its holdings in Zoetis by 30.8% in the 1st quarter. Amundi now owns 3,595,628 shares of the company’s stock worth $575,691,000 after buying an additional 846,909 shares in the last quarter. Finally, OVERSEA CHINESE BANKING Corp Ltd lifted its holdings in Zoetis by 475.9% in the 1st quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 900,261 shares of the company’s stock worth $148,228,000 after buying an additional 743,926 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Stock Performance

ZTS stock opened at $142.29 on Tuesday. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. The firm has a market cap of $63.06 billion, a P/E ratio of 24.49, a P/E/G ratio of 2.26 and a beta of 0.90. Zoetis Inc. has a 12-month low of $139.34 and a 12-month high of $196.55. The stock’s 50 day simple moving average is $149.04 and its 200 day simple moving average is $154.19.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.14. The business had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business’s revenue was up 4.2% compared to the same quarter last year. During the same period in the prior year, the company posted $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities research analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be paid a dividend of $0.50 per share. The ex-dividend date is Friday, October 31st. This represents a $2.00 annualized dividend and a yield of 1.4%. Zoetis’s dividend payout ratio is 34.42%.

Analyst Upgrades and Downgrades

ZTS has been the subject of a number of analyst reports. Argus reissued a “buy” rating and issued a $190.00 price target on shares of Zoetis in a report on Tuesday, September 9th. Leerink Partners lowered Zoetis from an “outperform” rating to a “market perform” rating and cut their target price for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. Stifel Nicolaus lowered Zoetis from a “buy” rating to a “hold” rating and cut their target price for the company from $165.00 to $160.00 in a research report on Wednesday, June 18th. Piper Sandler upped their price target on shares of Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Finally, Leerink Partnrs cut shares of Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Four equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $196.71.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.